ARIAD Pharmaceuticals (ARIA) has risen sharply, recording gains of 7.78% in the past 4 weeks. However, the stock has corrected -0.58% in the past 1 week, providing a good buying opportunity on dips. ARIAD Pharmaceuticals (ARIA) : Traders are bullish on ARIAD Pharmaceuticals (ARIA) as it has outperformed the S&P 500 by a wide margin of 8.01% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.07%, relative to the S&P 500.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.75% and the fifty day Moving Average is 19.26%. Ariad Pharmaceuticals Inc. is up 24.85% in the last three month period. Year-to-Date the stock performance stands at 64%.
ARIAD Pharmaceuticals (ARIA) : The most positive equity analysts on ARIAD Pharmaceuticals (ARIA) expects the shares to touch $13, whereas, the least positive believes that the stock will trade at $9 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $11 with an expected fluctuation of $1.83 from the mean.
ARIAD Pharmaceuticals (NASDAQ:ARIA): stock turned positive on Friday. Though the stock opened at $10.16, the bulls momentum made the stock top out at $10.34 level for the day. The stock recorded a low of $10.03 and closed the trading day at $10.25, in the green by 0.49%. The total traded volume for the day was 4,056,394. The stock had closed at $10.2 in the previous days trading.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).